Literature DB >> 18254726

Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.

Barbara Calamini1, Bernard D Santarsiero, Jean A Boutin, Andrew D Mesecar.   

Abstract

Melatonin exerts its biological effects through at least two transmembrane G-protein-coupled receptors, MT1 and MT2, and a lower-affinity cytosolic binding site, designated MT3. MT3 has recently been identified as QR2 (quinone reductase 2) (EC 1.10.99.2) which is of significance since it links the antioxidant effects of melatonin to a mechanism of action. Initially, QR2 was believed to function analogously to QR1 in protecting cells from highly reactive quinones. However, recent studies indicate that QR2 may actually transform certain quinone substrates into more highly reactive compounds capable of causing cellular damage. Therefore it is hypothesized that inhibition of QR2 in certain cases may lead to protection of cells against these highly reactive species. Since melatonin is known to inhibit QR2 activity, but its binding site and mode of inhibition are not known, we determined the mechanism of inhibition of QR2 by melatonin and a series of melatonin and 5-hydroxytryptamine (serotonin) analogues, and we determined the X-ray structures of melatonin and 2-iodomelatonin in complex with QR2 to between 1.5 and 1.8 A (1 A=0.1 nm) resolution. Finally, the thermodynamic binding constants for melatonin and 2-iodomelatonin were determined by ITC (isothermal titration calorimetry). The kinetic results indicate that melatonin is a competitive inhibitor against N-methyldihydronicotinamide (K(i)=7.2 microM) and uncompetitive against menadione (K(i)=92 microM), and the X-ray structures shows that melatonin binds in multiple orientations within the active sites of the QR2 dimer as opposed to an allosteric site. These results provide new insights into the binding mechanisms of melatonin and analogues to QR2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18254726      PMCID: PMC3265362          DOI: 10.1042/BJ20071373

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Databases in protein crystallography.

Authors:  G J Kleywegt; T A Jones
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-11-01

3.  Structure validation by Calpha geometry: phi,psi and Cbeta deviation.

Authors:  Simon C Lovell; Ian W Davis; W Bryan Arendall; Paul I W de Bakker; J Michael Word; Michael G Prisant; Jane S Richardson; David C Richardson
Journal:  Proteins       Date:  2003-02-15

4.  Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography.

Authors:  Zhirong Wang; Tze-chen Hsieh; Zhongtao Zhang; Yuliang Ma; Joseph M Wu
Journal:  Biochem Biophys Res Commun       Date:  2004-10-22       Impact factor: 3.575

5.  Model building and refinement practice.

Authors:  G J Kleywegt; T A Jones
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

6.  Crystallography & NMR system: A new software suite for macromolecular structure determination.

Authors:  A T Brünger; P D Adams; G M Clore; W L DeLano; P Gros; R W Grosse-Kunstleve; J S Jiang; J Kuszewski; M Nilges; N S Pannu; R J Read; L M Rice; T Simonson; G L Warren
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-09-01

7.  Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.

Authors:  François Mailliet; Gilles Ferry; Fanny Vella; Sylvie Berger; Francis Cogé; Pascale Chomarat; Catherine Mallet; Sophie-Pénélope Guénin; Gérald Guillaumet; Marie-Claude Viaud-Massuard; Saïd Yous; Philippe Delagrange; Jean A Boutin
Journal:  Biochem Pharmacol       Date:  2005-11-15       Impact factor: 5.858

8.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

9.  Crystal structure of human quinone reductase type 2, a metalloflavoprotein.

Authors:  C E Foster; M A Bianchet; P Talalay; Q Zhao; L M Amzel
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

10.  Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference.

Authors:  Pascale Chomarat; Francis Cogé; Sophie P Guénin; François Mailliet; Fanny Vella; Catherine Mallet; Stéphanie Giraudet; Nadine Nagel; Stéphane Leonce; Gilles Ferry; Philippe Delagrange; Jean A Boutin
Journal:  Biochimie       Date:  2007-07-15       Impact factor: 4.079

View more
  36 in total

1.  Cis-trans peptide variations in structurally similar proteins.

Authors:  Agnel Praveen Joseph; Narayanaswamy Srinivasan; Alexandre G de Brevern
Journal:  Amino Acids       Date:  2012-01-08       Impact factor: 3.520

2.  Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.

Authors:  Arup Maiti; P V Narasimha Reddy; Megan Sturdy; Laura Marler; Scott D Pegan; Andrew D Mesecar; John M Pezzuto; Mark Cushman
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

3.  Bioactive compounds from the fern Lepisorus contortus.

Authors:  Jian-Hong Yang; Tamara P Kondratyuk; Katherine C Jermihov; Laura E Marler; Xi Qiu; Yongsoo Choi; Hongmei Cao; Rui Yu; Megan Sturdy; Rong Huang; Ying Liu; Li-Qin Wang; Andrew D Mesecar; Richard B van Breemen; John M Pezzuto; Harry H S Fong; Ye-Gao Chen; Hong-Jie Zhang
Journal:  J Nat Prod       Date:  2011-01-24       Impact factor: 4.050

Review 4.  Resveratrol: Biological and pharmaceutical properties as anticancer molecule.

Authors:  Tze-chen Hsieh; Joseph M Wu
Journal:  Biofactors       Date:  2010 Sep-Oct       Impact factor: 6.113

5.  Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2.

Authors:  P V Narasimha Reddy; Katherine C Jensen; Andrew D Mesecar; Phillip E Fanwick; Mark Cushman
Journal:  J Med Chem       Date:  2011-12-29       Impact factor: 7.446

6.  Screening natural products for inhibitors of quinone reductase-2 using ultrafiltration LC-MS.

Authors:  Yongsoo Choi; Katherine Jermihov; Sang-Jip Nam; Megan Sturdy; Katherine Maloney; Xi Qiu; Lucas R Chadwick; Matthew Main; Shao-Nong Chen; Andrew D Mesecar; Norman R Farnsworth; Guido F Pauli; William Fenical; John M Pezzuto; Richard B van Breemen; Richard R van Breemen
Journal:  Anal Chem       Date:  2010-12-30       Impact factor: 6.986

7.  Chloroquine binding reveals flavin redox switch function of quinone reductase 2.

Authors:  Kevin K K Leung; Brian H Shilton
Journal:  J Biol Chem       Date:  2013-03-07       Impact factor: 5.157

8.  Precursor-Directed Generation of Amidine Containing Ammosamide Analogs: Ammosamides E-P.

Authors:  Ende Pan; Nathaniel W Oswald; Aaron G Legako; Janie M Life; Bruce A Posner; John B Macmillan
Journal:  Chem Sci       Date:  2013-01       Impact factor: 9.825

9.  Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells.

Authors:  Juanita Dortch-Carnes; Gianluca Tosini
Journal:  Exp Eye Res       Date:  2012-11-29       Impact factor: 3.467

10.  Quinone reductase 2 is a catechol quinone reductase.

Authors:  Yue Fu; Leonid Buryanovskyy; Zhongtao Zhang
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.